Data Sheet (Cat.No.T10820)

TargetMol

Ciraparantag

Chemical Properties



CAS No. : 1438492-26-2

Formula: C22H48N12O2

Molecular Weight: 512.7

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Ciraparantag is an inhibitor of thrombin and factor Xa. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including unfractionated heparin, low-molecular-weight heparin, and certain direct oral anticoagulants.
Targets(IC50)	Others
In vitro	Ciraparantag is a small synthetic and cationic molecule that binds direct Xa inhibitors, direct thrombin inhibitors, and unfractionated and low molecular weight heparin (LMWH) through non-covalent hydrogen bonds and charge-charge interactions [3].

Solubility Information

Solubility	H2O: 31 mg/mL (60.46 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9505 mL	9.7523 mL	19.5046 mL
5 mM	0.3901 mL	1.9505 mL	3.9009 mL
10 mM	0.195 mL	0.9752 mL	1.9505 mL
50 mM	0.039 mL	0.195 mL	0.3901 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25.

Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10.

Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44.

Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48(2):144-158.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481